JP2026053355A5 - - Google Patents

Info

Publication number
JP2026053355A5
JP2026053355A5 JP2025217417A JP2025217417A JP2026053355A5 JP 2026053355 A5 JP2026053355 A5 JP 2026053355A5 JP 2025217417 A JP2025217417 A JP 2025217417A JP 2025217417 A JP2025217417 A JP 2025217417A JP 2026053355 A5 JP2026053355 A5 JP 2026053355A5
Authority
JP
Japan
Prior art keywords
conjugate
fab
amino acid
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025217417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026053355A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/023381 external-priority patent/WO2021194913A1/en
Application filed filed Critical
Publication of JP2026053355A publication Critical patent/JP2026053355A/ja
Publication of JP2026053355A5 publication Critical patent/JP2026053355A5/ja
Pending legal-status Critical Current

Links

JP2025217417A 2020-03-24 2025-12-02 Tie2結合剤および使用方法 Pending JP2026053355A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202062993930P 2020-03-24 2020-03-24
US62/993,930 2020-03-24
US202063046318P 2020-06-30 2020-06-30
US63/046,318 2020-06-30
PCT/US2021/023381 WO2021194913A1 (en) 2020-03-24 2021-03-22 Tie2-binding agents and methods of use
JP2022556535A JP7720317B2 (ja) 2020-03-24 2021-03-22 Tie2結合剤および使用方法
JP2025086919A JP2025138630A (ja) 2020-03-24 2025-05-26 Tie2結合剤および使用方法
JP2025112744A JP2025163021A (ja) 2020-03-24 2025-07-03 Tie2結合剤および使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2025112744A Division JP2025163021A (ja) 2020-03-24 2025-07-03 Tie2結合剤および使用方法

Publications (2)

Publication Number Publication Date
JP2026053355A JP2026053355A (ja) 2026-03-25
JP2026053355A5 true JP2026053355A5 (cg-RX-API-DMAC10.html) 2026-04-16

Family

ID=75478286

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2022556535A Active JP7720317B2 (ja) 2020-03-24 2021-03-22 Tie2結合剤および使用方法
JP2025086919A Pending JP2025138630A (ja) 2020-03-24 2025-05-26 Tie2結合剤および使用方法
JP2025112744A Pending JP2025163021A (ja) 2020-03-24 2025-07-03 Tie2結合剤および使用方法
JP2025112743A Pending JP2025165931A (ja) 2020-03-24 2025-07-03 Tie2結合剤および使用方法
JP2025217418A Pending JP2026053356A (ja) 2020-03-24 2025-12-02 Tie2結合剤および使用方法
JP2025217417A Pending JP2026053355A (ja) 2020-03-24 2025-12-02 Tie2結合剤および使用方法

Family Applications Before (5)

Application Number Title Priority Date Filing Date
JP2022556535A Active JP7720317B2 (ja) 2020-03-24 2021-03-22 Tie2結合剤および使用方法
JP2025086919A Pending JP2025138630A (ja) 2020-03-24 2025-05-26 Tie2結合剤および使用方法
JP2025112744A Pending JP2025163021A (ja) 2020-03-24 2025-07-03 Tie2結合剤および使用方法
JP2025112743A Pending JP2025165931A (ja) 2020-03-24 2025-07-03 Tie2結合剤および使用方法
JP2025217418A Pending JP2026053356A (ja) 2020-03-24 2025-12-02 Tie2結合剤および使用方法

Country Status (17)

Country Link
US (3) US11999787B2 (cg-RX-API-DMAC10.html)
EP (1) EP4126949A1 (cg-RX-API-DMAC10.html)
JP (6) JP7720317B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220157445A (cg-RX-API-DMAC10.html)
CN (4) CN120757643A (cg-RX-API-DMAC10.html)
AU (1) AU2021242249A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018847A2 (cg-RX-API-DMAC10.html)
CA (1) CA3169967A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022002571A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022013937A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220489A (cg-RX-API-DMAC10.html)
IL (1) IL296528A (cg-RX-API-DMAC10.html)
MX (1) MX2022011752A (cg-RX-API-DMAC10.html)
PE (1) PE20230414A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022552267A1 (cg-RX-API-DMAC10.html)
TW (1) TWI901656B (cg-RX-API-DMAC10.html)
WO (1) WO2021194913A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3169967A1 (en) * 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
AU2023206363A1 (en) * 2022-01-13 2024-08-15 Ingenia Therapeutics Inc. Vegf and tie2-binding fusion protein and uses thereof
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN117233375B (zh) * 2023-09-06 2026-08-11 深圳市亚辉龙生物科技股份有限公司 用于荧光编码微球与抗原偶联的试剂盒及其应用
WO2025128706A1 (en) * 2023-12-11 2025-06-19 Massachusetts Eye And Ear Infirmary Methods of using tie-2 activators
KR20250128899A (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도
KR20250141637A (ko) * 2024-03-19 2025-09-29 주식회사 파멥신 서로 다른 세포의 Tie2에 트랜스 결합하는 항체 및 이의 용도
CN119569820B (zh) * 2024-12-04 2026-01-30 广西医科大学 一种合浦珠母贝体表粘液抗氧化活性肽及其制备和应用
WO2026156288A1 (en) * 2025-01-17 2026-07-23 Genentech, Inc. Methods for treatment of diabetic macular edema with an anti-tie2 antibody conjugate

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5144088A (en) 1991-04-26 1992-09-01 Aristech Chemical Corporation Manufacture of neopentyl glycol (I)
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
CA2140933A1 (en) 1992-08-21 1994-02-22 Paula M. Jardieu Method for treating an lfa-1 mediated disorder
CA2149048A1 (en) 1992-11-25 1994-06-09 George N. Cox Modified insulin-like growth factors
CN1134111A (zh) 1993-04-07 1996-10-23 赛纳根公司 使用胰岛素样生长因子结合蛋白质的方法
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ATE455171T1 (de) 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6365154B1 (en) 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
EP2348043A1 (en) 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
CN101528778A (zh) * 2006-08-18 2009-09-09 埃博灵克斯股份有限公司 用于治疗与il-6-介导的信号传导相关的疾病和病症的针对il-6r的氨基酸序列以及包括其的多肽
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US8957022B2 (en) 2006-10-27 2015-02-17 Sunnybrook Health Sciences Centre Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20110091462A1 (en) * 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN101724144A (zh) 2008-11-03 2010-06-09 北京键凯科技有限公司 新型的多臂聚乙二醇及其制备方法和应用
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
WO2010078063A1 (en) 2009-01-02 2010-07-08 Alcon Research, Ltd. In-situ refillable ophthalmic implant
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
US10316105B2 (en) * 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
EP3415533A1 (en) 2011-08-19 2018-12-19 Regeneron Pharmaceuticals, Inc. Anti-tie2 antibodies uses thereof
JP6051998B2 (ja) 2012-03-30 2016-12-27 日油株式会社 マルチアーム型ポリエチレングリコール誘導体、その中間体及び製造方法
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
WO2016010014A1 (ja) 2014-07-15 2016-01-21 アステラス製薬株式会社 新規抗ヒトTie2抗体
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
SI3215530T1 (sl) 2014-11-07 2020-02-28 Sesen Bio, Inc. Izboljšana protitelesa IL-6
TW201730211A (zh) * 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
IL290457B2 (en) * 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
WO2019235856A1 (ko) 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
EP3805265A4 (en) 2018-06-07 2022-07-06 Institute for Basic Science ANTIBODIES BINDING TO TIE2 AND USES THEREOF
CA3169967A1 (en) * 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use

Similar Documents

Publication Publication Date Title
JP2025138630A5 (cg-RX-API-DMAC10.html)
JP2022061992A5 (cg-RX-API-DMAC10.html)
JP2023129543A5 (cg-RX-API-DMAC10.html)
HRP20190932T1 (hr) Molekule protutijela koje se vežu na il-17a i il-17f
JP2012521191A5 (cg-RX-API-DMAC10.html)
JP2024167313A5 (cg-RX-API-DMAC10.html)
JP2023178323A5 (cg-RX-API-DMAC10.html)
JP2022512234A5 (cg-RX-API-DMAC10.html)
JP2021516960A5 (cg-RX-API-DMAC10.html)
JP2023166395A5 (cg-RX-API-DMAC10.html)
IL273285B1 (en) Anti- folate receptor alpha antibody conjugates and their uses
JP2003527861A5 (cg-RX-API-DMAC10.html)
RU2018130757A (ru) Конъюгаты антитела к cd74, композиции, содержащие конъюгаты антитела к cd74, и способы использования конъюгатов антитела к cd74
JP2009517057A5 (cg-RX-API-DMAC10.html)
JP2022506072A5 (cg-RX-API-DMAC10.html)
HRP20170374T1 (hr) Biološki proizvodi
JP2022512778A5 (cg-RX-API-DMAC10.html)
JP2006506955A5 (cg-RX-API-DMAC10.html)
JP2022516503A5 (cg-RX-API-DMAC10.html)
JP2023519213A5 (cg-RX-API-DMAC10.html)
JP2023519776A5 (cg-RX-API-DMAC10.html)
JP2025183307A5 (cg-RX-API-DMAC10.html)
JP2005510246A5 (cg-RX-API-DMAC10.html)
JP2024086870A5 (cg-RX-API-DMAC10.html)
JP2012532851A5 (cg-RX-API-DMAC10.html)